Insights from CGTW16 – Part 3: Clinical trials, health economics and regulatory affairs
Amin Adibi is a biomedical engineer and a research assistant at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness...Insights from CGTW16 – Part 2: scale-up challenges and closed systems
Amin Adibi is a biomedical engineer and a research assistant at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness...Right Turn: What do the results of the U.S. election mean for science?
This isn’t the blog that I planned to write this week, but I’m so preoccupied with the outcome of the U.S. election, I’m finding it hard to focus on anything else right now. So, let’s look at the implications of a Trump presidency on science. An article in Nature...Right Turn: The story of scurvy is a poignant cautionary tale for modern medical science
Elizabeth (Liz) Csaszar is a development manager for the BridGE team at CCRM. Her areas of interest are cell manufacturing, clinical translation of cell based therapies, and blood cell technologies. Liz obtained her PhD at the University of Toronto, focusing on the...Lobbying for deregulation of stem cell procedures is giving rise to a new “dark economy”
Day 3 of the Till & McCulloch Meetings continued with many interesting talks. The one that I have chosen to write about in more detail Dr. Douglas Sipp’s, titled “The Stem Cell Dark Economy.” I think his talk was really thought provoking, and important to be...
Comments